Cogent Biosciences (COGT) Net Cash Flow (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Net Cash Flow of -$70.8 million for Q1 2026, down 354.34% year-over-year from $27.8 million in Q1 2025, and down 137.9% quarter-over-quarter from $186.8 million in Q4 2025.
Cogent Biosciences (COGT) Net Cash Flow (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Net Cash Flow for 10 consecutive years, with -$70.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 354.34% year-over-year to -$70.8 million; the TTM figure through Mar 2026 stood at $115.6 million (up 228.76% YoY), while the FY2025 annual figure was $214.3 million, up 376.82% from the prior year.
- Net Cash Flow retreated to -$70.8 million in Q1 2026 per COGT's latest filing, from $186.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $186.8 million in Q4 2025 and bottomed at -$185.0 million in Q3 2022.
- Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 4823.9% — and 2025, when it jumped 16578.12%.
- Cogent Biosciences' Net Cash Flow stood at -$682000.0 in 2022, then plunged by 4823.9% to -$33.6 million in 2023, then soared by 103.34% to $1.1 million in 2024, then surged by 16578.12% to $186.8 million in 2025, then plunged by 137.9% to -$70.8 million in 2026.
- Business Quant data shows COGT's Net Cash Flow at -$70.8 million in Q1 2026, $186.8 million in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -60.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.04 Mn |
| Jun 30, 2026 | -60.04 Mn |
| Mar 31, 2026 | -70.80 Mn |
| Mar 31, 2026 | -70.80 Mn |
| Dec 31, 2025 | 186.80 Mn |
| Dec 31, 2025 | 186.80 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 27.84 Mn |
| Mar 31, 2025 | 27.84 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 8.83 Mn |
| Sep 30, 2024 | 8.83 Mn |
| Jun 30, 2024 | -127.58 Mn |
| Jun 30, 2024 | -127.58 Mn |
| Mar 31, 2024 | 162.57 Mn |
| Mar 31, 2024 | 162.57 Mn |